Aaptocarbamates A-G, chlorinated terpene carbamates with antiosteoclastogenic activities from the marine sponge Aaptos sp

Ircindrimanes A-I, nine undescribed meroterpenoids with cytotoxic activities from the marine sponge Ircinia sp

Nine undescribed meroterpenoids, named ircindrimanes A-I (1-9), were isolated from the marine sponge Ircinia sp. collected in the South China Sea. Their planar structures were determined by NMR, HRESIMS, UV spectroscopic data. The absolute configurations were established through DP4+ analysis, ECD calculations and single crystal X-ray diffraction. Biological evaluation indicated that compounds 7 and 8 exhibited moderate to strong cytotoxic activities towards several cancer cell lines.

Marine natural products

Covering: January to the end of December 2023This review covers the literature published in 2023 for marine natural products (MNPs), with 582 citations (541 for the period January to December 2023) referring to compounds isolated from marine microorganisms and phytoplankton, green, brown and red algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, the submerged parts of mangroves and other intertidal plants. The emphasis is on new compounds (1220 in 340 papers for 2023), together with the relevant biological activities, source organisms and country of origin. Pertinent reviews, biosynthetic studies, first syntheses, and syntheses that led to the revision of structures or stereochemistries, have been included. An analysis of the progress in the study of prokaryote involvement in macro-invertebrate MNP production is discussed.

Metabolic bone disorders and the promise of marine osteoactive compounds

Metabolic bone disorders and associated fragility fractures are major causes of disability and mortality worldwide and place an important financial burden on the global health systems. These disorders result from an unbalance between bone anabolic and resorptive processes and are characterized by different pathophysiological mechanisms. Drugs are available to treat bone metabolic pathologies, but they are either poorly effective or associated with undesired side effects that limit their use. The molecular mechanism underlying the most common metabolic bone disorders, and the availability, efficacy, and limitations of therapeutic options currently available are discussed here. A source for the unmet need of novel drugs to treat metabolic bone disorders is marine organisms, which produce natural osteoactive compounds of high pharmaceutical potential. In this review, we have inventoried the marine osteoactive compounds (MOCs) currently identified and spotted the groups of marine organisms with potential for MOC production. Finally, we briefly examine the availability of in vivo screening and validation tools for the study of MOCs.